Olmesartan
- Atc Codes:C09CA08
- CAS Codes:144689-63-4
- PHARMGKB ID:144689-63-4
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Mencord, Olmetec; Belgium: Belsar, Olmetec; Bulgaria: Tensar; Czech Republic: Olmetec, Sarten; Denmark: Benetor, Olmetec; Estonia: Mesar; Finland: Benetor, Olmetec; France: Alteis, Olmes, Olmetec; Germany: Belsar, Mencord, Olmes, Olmetec, Votum; Greece: Olartan, Olmetec; Hungary: Laresin, Olmetec; Ireland: Benetor, Omesar; Italy: Olmetec, Olpress, Plaunac; Lithuania: Mesar; Netherlands: Olmetec; Portugal: Olmetec, Olsar; Romania: Santini; Slovakia: Olmetec, Tenzar; Spain: Olmetec, Openvas; UK: Olmetec.
North America
Canada: Olmetec; USA: Benicar, Olmesartan.
Latin America
Argentina: Olmec, Olmetec, Tensonit; Brazil: Benicar, Olmetec; Mexico: Almetec.
Asia
Japan: Olmetec.
Drug combinations
Olmesartan and Amlodipine
Olmesartan and Hydrochlorothiazide
Olmesartan, Amlodipine and Hydrochlorothiazide
Chemistry
Olmesartan Medoxomil: C~29~H~30~N~6~O~6~. Mw: 558.59. 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2′-(1H-tetrazol-5-yl) [1,1′-biphenyl]-4-yl]methyl]-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester. CAS-144689-63-4 (2002).
Pharmacologic Category
Angiotensin II Receptor Antagonists. (ATC-Code: C09CA08).
Mechanism of action
Blocks vasoconstrictor and aldosterone-secreting effects of angiotensin II. Interacts reversibly at AT1 and AT2 receptors and has slow dissociation kinetics (has greater affinity for AT1 receptor). Olmesartan increases urinary flow rate and, besides being natriuretic and kaliuretic, increases excretion of chloride, magnesium, uric acid, calcium, and phosphate.
Therapeutic use
Hypertension.
Pregnancy and lactiation implications
Medications which act on renin-angiotensin system reported to produce fetal/neonatal hypotension, skull hypoplasia, anuria, renal failure, and death. Oligohydramnios also reported. These effects reported to occur with exposure during 2^nd^ and 3^rd^ trimesters. There are no adequate, well-controlled studies in pregnant women. Angiotensin receptor blockers should be discontinued as soon as possible once pregnancy is detected. Excretion in breast milk unknown (contraindicated in nursing women).
Unlabeled use
Contraindications
Hypersensitivity to olmesartan or any component of the formulation.
Warnings and precautions
Hyperkalemia may occur (higher risk if renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium containing salts). May be associated with deterioration of renal function and/or increases in serum creatinine. Use caution in significant aortic/mitral stenosis. Use olmesartan with caution in unstented unilateral/bilateral renal artery stenosis, and with pre-existing renal insufficiency and severe renal impairment. Drugs which act on angiotensin system can cause injury and death to developing fetus when used in 2^nd^ and 3^rd^ trimesters.